Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 9/20 | 0.41 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2B | P41595 | 6/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286798 | 0.77 | MTNR1A (0.43) | CYP19A1HTR2CHTR2AHTR2BMTNR1A | |
| SCHEMBL286695 | 0.76 | TSHR (0.43) | CYP19A1HTR2CHTR2AHTR2BMTNR1A | |
| SCHEMBL20906483 | 0.74 | MAOA (0.44) | BRD4 | |
| SCHEMBL28775654 | 0.73 | PDE4D (0.41) | MTNR1AMTNR1BBRD4 | |
| SCHEMBL296779 | 0.72 | MTNR1A (0.40) | CYP19A1HTR2CHTR2AHTR2BMTNR1A | |
| SCHEMBL286893 | 0.72 | TSHR (0.38) | CYP19A1HTR2CHTR2AHTR2BMTNR1A | |
| SCHEMBL11224510 | 0.70 | HTR2C (0.48) | CYP19A1HTR2CHTR2AHTR2B | |
| SCHEMBL7611834 | 0.70 | CA1 (0.46) | CYP19A1HTR2A | |
| SCHEMBL298452 | 0.69 | KDM4E (0.31) | — | |
| SCHEMBL13705941 | 0.68 | HTR2C (0.59) | CYP19A1HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427444-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | CYP19A1 4155/4885HTR2C 3346/4885HTR2A 3252/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | CYP19A1 4155/4885HTR2C 3346/4885HTR2A 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.